Amoy Diagnostics Co Ltd (300685)

Currency in CNY
23.37
-0.29(-1.23%)
Closed·
300685 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
300685 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.2023.88
52 wk Range
17.4728.79
Key Statistics
Bid/Ask
23.37 / 23.37
Prev. Close
23.66
Open
23.66
Day's Range
23.2-23.88
52 wk Range
17.47-28.79
Volume
8.77M
Average Volume (3m)
8.31M
1-Year Change
22.9%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300685 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.08
Upside
+24.41%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Amoy Diagnostics Co Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Amoy Diagnostics Co Ltd Company Profile

Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel, detects EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel, detects single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is based in Xiamen, China.

Employees
1144
Market
China

Compare 300685 to Peers and Sector

Metrics to compare
300685
Peers
Sector
Relationship
P/E Ratio
30.5x32.9x−0.5x
PEG Ratio
3.58−0.010.00
Price/Book
4.9x2.4x2.6x
Price / LTM Sales
8.0x6.9x3.3x
Upside (Analyst Target)
26.9%2.2%43.4%
Fair Value Upside
Unlock14.2%7.1%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.08
(+24.41% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.76%
Dividend Yield
1.28%
Industry Median 1.84%
Annualised payout
0.30
Paid annually
5-Years Growth
+26.50%
Growth Streak

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
0.25 / 0.22
Revenue / Forecast
307.13M / 370.42M
EPS Revisions
Last 90 days

300685 Income Statement

FAQ

What Stock Exchange Does Amoy Diagnostics Trade On?

Amoy Diagnostics is listed and trades on the Shenzhen Stock Exchange stock exchange.

What Is the Stock Symbol for Amoy Diagnostics?

The stock symbol for Amoy Diagnostics is "300685."

What Is the Amoy Diagnostics Market Cap?

As of today, Amoy Diagnostics market cap is 9.04B.

What Is Amoy Diagnostics's Earnings Per Share (TTM)?

The Amoy Diagnostics EPS (TTM) is 0.76.

When Is the Next Amoy Diagnostics Earnings Date?

Amoy Diagnostics will release its next earnings report on 27 Oct 2025.

From a Technical Analysis Perspective, Is 300685 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Amoy Diagnostics Stock Split?

Amoy Diagnostics has split 3 times.

How Many Employees Does Amoy Diagnostics Have?

Amoy Diagnostics has 1144 employees.

What is the current trading status of Amoy Diagnostics (300685)?

As of 08 Aug 2025, Amoy Diagnostics (300685) is trading at a price of 23.37, with a previous close of 23.66. The stock has fluctuated within a day range of 23.20 to 23.88, while its 52-week range spans from 17.47 to 28.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.